M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Redx to acquire Jounce Therapeutics, Inc.
Announced Feb 23, 2023 · Terminated Mar 27, 2023
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock
Transaction
- Acquirer
- Redx
- Target
- Jounce Therapeutics, Inc. (JNCE)
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Terminated Mar 27, 2023
Deal protections
Not yet read from the merger agreement.
Advisors
- To the acquirer
- Centerview
- To the target
- TD Cowen
Sector context · Healthcare
- Comparable deals
- 77 in the prior 24 months
- Premium
- Sector median 47.1%
- EV / Adj. EBITDA
- Sector median 21.3x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedFeb 23, 2023
- Tender offerMar 27, 2023
- TerminatedMar 27, 2023